EU market-access pathway for BCMA bispecifics is bifurcating

Reading the signal

Three BCMA bispecific antibodies are now approved in the EU for relapsed-refractory multiple myeloma. The pivotal evidence and the regulatory labels are not the limiting factor on real-world access; the divergence sits at the HTA, payer and clinical-pathway layer in each country.

Reading across Germany, France, the UK, Italy and Spain:

• Prior-line requirements range from "after at least three prior therapies including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody" to broader earlier-line criteria in some settings, with material implications for the eligible population
• Use-setting expectations range from "infusion in any haematology centre" to "restricted to specialist centres with documented cytokine-release-syndrome management capacity", with material implications for patient access geography
• Post-marketing evidence demands range from outcomes-based managed-entry agreements with active registries to standard listing decisions

The class-level efficacy and toxicity data are common across markets. The variance is at the access layer, and it is wider than for prior multiple myeloma classes.

Commercial implications

For sponsors of BCMA bispecific assets, GPRC5D bispecific assets, and adjacent CAR-T programmes:

1. A single European commercial narrative no longer fits the class. Country-specific framing on prior-line position, use-setting and evidence demands is now the table stakes for a BCMA bispecific commercial team.
2. The post-marketing evidence layer is becoming the differentiating asset. Sponsors that can credibly run outcomes-based registries with HTA-relevant endpoints across the major markets are positioned to outpace sponsors that cannot.
3. The earlier-line opportunity will compress this divergence, not resolve it. As BCMA bispecifics move into earlier lines, country-specific positioning will harden around the line they are accessible at, not converge on a class label.

What we are watching

• NICE Technology Appraisal updates and managed-access agreement framing for the second and third bispecific entrants.
• G-BA early benefit assessments and AMNOG decisions on the post-launch BCMA bispecifics.
• The rate at which BCMA bispecifics move into earlier lines through label extensions and what that does to the country-specific access shapes.